2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163669
    ITI-333 2117619-00-6
    ITI-333 is a tetracyclic compound with oral bioavailability and analgesic activity, targeting multiple receptors. ITI-333 can be used for research on various forms of pain.
    ITI-333
  • HY-163671
    PW0729 2767348-36-5
    PW0729 (compound 15b) is an orphan GPR52 agonist with potential applications in GPR52 activation, signaling bias, and neuropsychiatric and neurological disorders. The brain exposure characteristics of PW0729 need to be further optimized.
    PW0729
  • HY-163703
    D4R antagonist-2
    D4R antagonist-2 (compound 33) is a D4R antagonist. D4R antagonist-2 has a IC50 value of 210 nM, and a Ki value of 59 nM for D4R. D4R antagonist-2 can be used in the Parkinson's disease research.
    D4R antagonist-2
  • HY-163718
    Ferroptosis-IN-9
    Ferroptosis-IN-9 (compound 23b) is a ferroptosis inhibitor with an IC50 value of >30uM for hERG inhibition. Ferroptosis-IN-9 is a ROS scavenger. Ferroptosis-IN-9 can be used in neurodegenerative disease research.
    Ferroptosis-IN-9
  • HY-163728
    DSP-6745 2235409-96-6
    DSP-6745 is a potent and orally active 5-HT Receptor inhibitor. DSP-6745 can be used in the study of depressive disorder.
    DSP-6745
  • HY-163746
    BuChE-IN-11
    BuChE-IN-11 (Compound 3b-1) is an selective BuChE inhibitor with an IC50 of 0.44 μM for hBuChE. BuChE-IN-11 has high blood-brain barrier permeability and exhibits strong antioxidant activity due to its free radical scavenging properties. BuChE-IN-11 interacts with the choline binding site, acetyl binding site, and peripheral anionic site, exhibiting submicromolar BuChE inhibitory activity and preventing β-amyloid (Aβ) self-aggregation. BuChE-IN-11 holds promise for research in the field of Alzheimer's disease.
    BuChE-IN-11
  • HY-163772
    Fraxinellone analog 1
    Fraxinellone analog 1 (compound 2) is a potent and rapid activator of the Nrf2 mediated antioxidant defense system, which protects against glutamate-mediated excitotoxicity and induces the expression of antioxidant genes Gpx4, Sod1, and Nqo1. Fraxinellone analog 1 has neuroprotective effects and regulatory effects against oxidative stress and inflammation, and can be used in the study of neurodegenerative diseases.
    Fraxinellone analog 1
  • HY-163779
    β-Glucocerebrosidase modulator 1
    β-Glucocerebrosidase modulator 1 (Compound 28) is an allosteric modulator for β-Glucocerebrosidase with an EC50 of 9.0 μM and a Kd of 0.050 μM.
    β-Glucocerebrosidase modulator 1
  • HY-163795
    GPR183-IN-1 2924063-70-5
    GPR183-IN-1 (compound 15) is a potent and orally activity GPR183 inhibitor. GPR183-IN-1 inhibits Ca2+ mobilization with an IC50 value of 39.97 nM. GPR183-IN-1 has the potential for the research of cancer, autoimmune diseases, pain, and osteoporosis.
    GPR183-IN-1
  • HY-163801
    Nurr1 agonist 9
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable.
    Nurr1 agonist 9
  • HY-163802
    Nurr1 agonist 10
    Nurr1 agonist 10 (compound 37) is a potent Nurr1 agonist with an EC50 value of 40 nM. Nurr1 agonist 10 has the potential for the research of Parkinson’s and Alzheimer’s disease.
    Nurr1 agonist 10
  • HY-163806
    NT376 2820208-97-5
    NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases.
    NT376
  • HY-16381B
    Pasireotide (diaspartate) 1421446-02-7
    Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity.
    Pasireotide (diaspartate)
  • HY-163825
    RNB-61
    RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the Ki ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain.
    RNB-61
  • HY-163830
    Pegasus
    Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease.
    Pegasus
  • HY-163831
    AZ12559322 947184-66-9
    AZ12559322 is a positive allosteric modulator of mGluR2, with the Ki value of 1.31 nM. AZ12559322 can be used in neurological research.
    AZ12559322
  • HY-163840
    GFRα2/3-IN-1
    GFRα2/3-IN-1 (Compound 16) is a selective GFRα2/3 inhibitor with IC50 values of 0.1 and 0.2 μM for GFRα2 and GFRα3, respectively. GFRα2 is a glial cell line-derived neurotrophic factor (GDNF) receptor related to GFRα1, GFRα2/3-IN-1 can be used for pain and itch research.
    GFRα2/3-IN-1
  • HY-163861
    Tl45b
    Tl45b is an AChE inhibitor, with an IC50 of 0.71 μM. Tl45b can be used for the research of Alzheimer’s disease.
    Tl45b
  • HY-163879
    hMAO-B-IN-9
    hMAO-B-IN-9 (Compound 25c) is a non-competitive inhibitor for monoamine oxidase B (MAO-B) with an IC50 of 1.58 µM (hMAO-B). hMAO-B-IN-9 forms complex with iron ions as a chelator, and inhibits Erastin (HY-15763)-induced ferroptosis. hMAO-B-IN-9 exhibits antioxidant activity by downregulating the level of reactive oxygen species (ROS). hMAO-B-IN-9 improves cognitive function in mice, without significant toxicity (30 mg/kg). hMAO-B-IN-9 is blood-brain barrier permeable, according to the in silico prediction.
    hMAO-B-IN-9
  • HY-163883
    BChE-IN-34 2215768-12-8
    BChE-IN-34 is a potent and selective butyrylcholinesterase (BChE) inhibitor with an IIC50 of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects.
    BChE-IN-34
Cat. No. Product Name / Synonyms Application Reactivity